{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MS&page=2",
    "query": {
      "condition": "MS",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MS&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-27T00:04:59.857Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04855825",
      "title": "Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Multiple Sclerosis",
        "Gait Disorders, Neurologic",
        "Motility Disorder",
        "Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "Robotic Exoskeleton Rehabilitation",
          "type": "DEVICE"
        },
        {
          "name": "Conventional Gait Therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Kessler Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 10,
      "start_date": "2017-10-05",
      "completion_date": "2027-12-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-24",
      "last_synced_at": "2026-06-27T00:04:59.857Z",
      "location_count": 1,
      "location_summary": "West Orange, New Jersey",
      "locations": [
        {
          "city": "West Orange",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04855825"
    },
    {
      "nct_id": "NCT01034579",
      "title": "The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Relapsing Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Blood sampling",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 324,
      "start_date": "2010-02",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2014-03-10",
      "last_synced_at": "2026-06-27T00:04:59.857Z",
      "location_count": 1,
      "location_summary": "Rockland, Massachusetts",
      "locations": [
        {
          "city": "Rockland",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01034579"
    },
    {
      "nct_id": "NCT04574024",
      "title": "HFS (High-Fiber Supplement) in MS (Multiple Sclerosis)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "NBT-NM108",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Suhayl Dhib-Jalbut, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "21 Years to 55 Years"
      },
      "enrollment_count": 7,
      "start_date": "2022-03-21",
      "completion_date": "2024-07-15",
      "has_results": true,
      "last_update_posted_date": "2024-12-17",
      "last_synced_at": "2026-06-27T00:04:59.857Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04574024"
    },
    {
      "nct_id": "NCT00001669",
      "title": "A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "rhIGF-1 (CEP-151)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 15,
      "start_date": "1997-07",
      "completion_date": "2000-04",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-06-27T00:04:59.857Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001669"
    },
    {
      "nct_id": "NCT07225361",
      "title": "Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis",
        "Multiple Sclerosis (MS) - Relapsing-remitting"
      ],
      "interventions": [
        {
          "name": "Ublituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 40,
      "start_date": "2025-11-28",
      "completion_date": "2029-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-06-27T00:04:59.857Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07225361"
    },
    {
      "nct_id": "NCT04495556",
      "title": "Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "MRI",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 420,
      "start_date": "2020-06-11",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-02",
      "last_synced_at": "2026-06-27T00:04:59.857Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04495556"
    },
    {
      "nct_id": "NCT04445116",
      "title": "Endeavor™ in Pediatric MS",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Action Video Game Treatment",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "22 Years",
        "sex": "ALL",
        "summary": "12 Years to 22 Years"
      },
      "enrollment_count": 0,
      "start_date": "2023-01",
      "completion_date": "2023-02-23",
      "has_results": false,
      "last_update_posted_date": "2023-05-06",
      "last_synced_at": "2026-06-27T00:04:59.857Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04445116"
    },
    {
      "nct_id": "NCT02413918",
      "title": "Iloperidone in Mixed States of Bipolar Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "iloperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2012-04",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2018-02-08",
      "last_synced_at": "2026-06-27T00:04:59.857Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02413918"
    },
    {
      "nct_id": "NCT00239993",
      "title": "A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "glatiramer acetate",
          "type": "DRUG"
        },
        {
          "name": "Warm compress prior to injection of glatiramer acetate",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Teva Neuroscience, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 50,
      "start_date": "2005-08",
      "completion_date": "2006-02",
      "has_results": false,
      "last_update_posted_date": "2017-02-06",
      "last_synced_at": "2026-06-27T00:04:59.857Z",
      "location_count": 6,
      "location_summary": "Fullerton, California • Miami, Florida • Springfield, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Springfield",
          "state": "Massachusetts"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00239993"
    },
    {
      "nct_id": "NCT00401115",
      "title": "Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetic Macular Edema",
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "MS-R001 (rapamycin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2006-09",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2010-07-26",
      "last_synced_at": "2026-06-27T00:04:59.857Z",
      "location_count": 2,
      "location_summary": "Phoenix, Arizona • Arlington, Texas",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Arlington",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00401115"
    }
  ]
}